H.C. Wainwright lowered the firm’s price target on Ekso Bionics (EKSO) to $4 from $9 and keeps a Buy rating on the shares following the Q1 report. The company saw softer enterprise revenue due to customer budget cuts, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKSO: